Jacques Volckmann

Jacques Volckmann serves as the head of R&D France at Sanofi since April 2018 and has held the position of CEO at Sanofi Vaccine Technologies SAS since June 2014. In addition, Jacques has been an associate vice president at Sanofi Pasteur since January 2010, overseeing the management of R&D sites, scientific support functions, and interactions within the R&D ecosystem. Notable achievements include the successful registration of the IMOJEV vaccine in Australia and Thailand and the development of Hexaxim, a hexavalent pediatric combination vaccine. Jacques also holds the position of president of the board of directors at ISPB, Faculté de Pharmacie de Lyon, and possesses advanced degrees in various pharmaceutical disciplines from Université Claude Bernard Lyon 1.